Payment overview · 2025
General Payments
$90.74
5 reported records · 5 companies
Healthcare provider profile · identity verified
Alejandro Perez, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALEXANDRIA, LA · NPI 1598768301
Verified facts
What the public records show
CMS Open Payments records show Alejandro Perez, MD received $90.74 in general payments during 2025 across 5 reported records.
Axsome Therapeutics, Inc. accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.45 | 24.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.04 | 22.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.86 | 19.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.76 | 18.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.63 | 15.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $90.74 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 296 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 231 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 230 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 192 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 51 |
| Gabapentin | Gabapentin | 156 | 39 |
| Alprazolam | Alprazolam | 144 | 26 |
| Losartan Potassium | Losartan Potassium | 144 | 45 |
| Tramadol Hcl | Tramadol Hcl | 118 | 20 |
| Glimepiride | Glimepiride | 111 | 28 |
| Omeprazole | Omeprazole | 107 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 29 |
| Furosemide | Furosemide | 99 | 26 |
| Lisinopril | Lisinopril | 96 | 33 |
| Metformin Hcl Er | Metformin Hcl | 95 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 27 |
| Clonazepam | Clonazepam | 85 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 21 |
| Metformin Hcl | Metformin Hcl | 84 | 23 |
| Meloxicam | Meloxicam | 83 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 28 |
| Trazodone Hcl | Trazodone Hcl | 75 | 24 |
| Ozempic | Semaglutide | 74 | suppressed |
| Allopurinol | Allopurinol | 72 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 27 |
| Jardiance | Empagliflozin | 66 | 13 |
| Alendronate Sodium | Alendronate Sodium | 63 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 18 |
| Lorazepam | Lorazepam | 60 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 20 |
| Potassium Chloride | Potassium Chloride | 59 | 22 |
| Ezetimibe | Ezetimibe | 58 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 23 |
| Mounjaro | Tirzepatide | 57 | suppressed |
| Atenolol | Atenolol | 55 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | 12 |
| Methylprednisolone | Methylprednisolone | 51 | 44 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 15 |
| Bupropion Xl | Bupropion Hcl | 48 | 15 |
| Simvastatin | Simvastatin | 46 | 14 |
| Montelukast Sodium | Montelukast Sodium | 45 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | 12 |
| Azelastine Hcl | Azelastine Hcl | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | 12 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 11 |
| Torsemide | Torsemide | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Eszopiclone | Eszopiclone | 33 | suppressed |
| Prednisone | Prednisone | 33 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | suppressed |
| Estradiol | Estradiol | 32 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | 13 |
| Eliquis | Apixaban | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 23 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Sucralfate | Sucralfate | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Flurbiprofen | Flurbiprofen | 22 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 14 |
| Valsartan | Valsartan | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 16 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Trandolapril | Trandolapril | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $90.74 · 5 records | Axsome Therapeutics, Inc. | Auvelity, CAPLYTA, MOUNJARO, Ozempic, Veozah, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error